Gynecological cancers, including ovarian, cervical, uterine, and endometrial cancers, remain some of the most complex malignancies to study. While survival has improved in many cancers, uterine corpus cancer is trending upward; in 2025, the U.S. is expected to see 69,120 new cases and 13,860 deaths, and mortality increased about 1.5% per year from 2013 to 2022. These trends point to the need for deeper molecular data to guide translational research.

Bioinformatics plays a vital role in analyzing complex high-throughput sequencing data, particularly in the realm of single cell research. The ability to analyze and interpret massive amounts of single cell data has revolutionized our understanding of cellular heterogeneity and its implications in various biological processes. The blog explores the capabilities of bioinformatics team at MedGenome in analyzing single cell sequencing data. Here, we explore different types of bioinformatics reports, the importance of data visualization and generation of interactive reports such as differential gene expression analysis, heatmap visualization, interactive tSNE plots with cell type and cluster information.

NGS technologies is at the forefront of Biological Research. They produce enormous data running into gigabases in a single round of sequencing. However, several sequencing artifacts such as read errors (base calling errors and small insertions/deletions), poor quality reads and primer/adaptor contamination are quite common with the NGS data obtained after sequencing. It can impose significant impact on the downstream analysis such as sequence assembly, single nucleotide polymorphisms (SNP) identification and gene expression studies.

Our journey in 2022 was focused on providing the utmost customer experience for the services and solutions that we delivered to you. Along with expanding our portfolio of services and solutions – the tissue dissociation and nuclei isolation services to support our single cell customers, streamlined antibody discovery using high-throughput single B cell receptor sequencing, TSO500 targeted panels for oncology research, single cell and bulk epigenetics assays. We improved our turn-around times on bulk transcriptomics, whole exome and whole genome projects by incorporating automation at multiple project stages and installing new sequencing capacity in 2022. Our sequencing team has delivered high-quality data consistently for a variety of library types throughout the year.

Emerging single-cell technologies have provided us with a powerful tool to dissect the clonal complexity of tumor cells, deconvolute the role of immune cell types in disease mechanisms, and monitor risk and treatment strategies to guide early patient diagnosis, since being highlighted as the ‘method of the year’ in 2013. As our capabilities in single cell sequencing continue to increase, latest advances in multi-omics of single cells are providing newer ways of integrating single cell transcriptomics with the multiple molecular measurements in a single experiment.

Technological advances in sequencing capabilities have rapidly accelerated our understanding of human health and disease. From the workhorse short-read Illumina sequencing data to the recent advent of third-generation sequencing instruments such as PacBio, Nanopore, that now enable single molecule sequencing, genomics and its applications has assumed a wider scope in recent times ranging from specialised studies such as transcriptomics, epigenomics, metagenomics to more specific application areas such as biomarker discovery, pharmacogenomics, disease diagnosis, identification of novel genes in disease mechanisms, drug repurposing and disease risk predictions.

Cancer immunologists scooped the 2018 medicine noble prize for pioneering treatments that unleash the body’s own immune system to attack cancer cells. It represents a completely new principle which unlike the previous strategies that target the cancer cells, rather targets the brakes — the checkpoints — of the host immune system.